BioCentury
ARTICLE | Clinical News

RGX-121 regulatory update

August 8, 2016 7:00 AM UTC

FDA granted Rare Pediatric Disease designation to RegenxBio’s RGX-121 to treat mucopolysaccharidosis type II (MPS II Hunter’s syndrome). RegenxBio said it intends to submit INDs for both RGX-121, an a...